A novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture

Journal of Pharmacological Sciences

Volumn 123, Issue 2, 2013, Pages 110-119

  Pan, Si Yuan ^a   Jia, Zhan Hong ^a   Zhang, Yi ^a   Yu, Qing ^a   Wang, Xiao Yan ^a   Sun, Nan ^a   Zhu, Pei Li ^a   Yu, Zhi Ling ^b   Ko, Kam Ming ^c  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^c HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Combined hyerlipidemia; Fenofibrate; Hepatic steatosis; Hepatomegaly; Schisandrin B

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE SALT; CHOLESTEROL; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SCHIZANDRIN B; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY LIVER; HYPERLIPIDEMIA; LIPID STORAGE; LIVER CELL DAMAGE; LIVER FUNCTION; LIVER INJURY; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; BILE ACIDS AND SALTS; CHOLESTEROL; CYCLOOCTANES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; FATTY LIVER; FENOFIBRATE; HYPERLIPIDEMIAS; LIGNANS; LIPOPROTEINS; MALE; MICE; MICE, INBRED ICR; POLYCYCLIC COMPOUNDS; TIME FACTORS; TRIGLYCERIDES;

EID: 84888612415     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13087FP     Document Type: Article

References (41)

1. Yoon PW, Tong X, Schmidt SM, Matson-Koffman D. Clinical preventive services for patients at risk for cardiovascular disease, national ambulatory medical care survey, 2005-2006. Prev Chronic Dis. 2011;8:A43.
2. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
3. Souza MR, Diniz Mde F, Medeiros-Filho JE, Araújo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012;49:89-96.
4. Rogi T, Tomimori N, Ono Y, Kiso Y. The mechanism underlying the synergetic hypocholesterolemic effect of sesamin and α-tocopherol in rats fed a high-cholesterol diet. J Pharmacol Sci. 2011;115:408-416.
5. Ackerman Z, Grozovski M, Oron-Herman M, Rosenthal T, Sela BA, Amir G. Effects of antihypertensive and triglyceride lowering agents on splenocyte apoptosis in rats with fatty liver. Basic Clin Pharmacol Toxicol. 2013;113:37-42.
6. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol. 2007;27:1706-1721.
7. Ma Y, Wang W, Zhang J, Lu Y, Wu W, Yan H, et al. Hyperlipidemia and atherosclerotic lesion development in ldlr-deficient mice on a long-term high-fat diet. PLoS One. 2012;7:e35835.
8. Chen Y, Curran CP, Nebert DW, Patel KV, Williams MT, Vorhees CV. Effect of chronic glutathione deficiency on the behavioral phenotype of Gclm(-/-) knockout mice. Neurotoxicol Teratol. 2012;34:450-457.
9. van der Hoorn JW, Jukema JW, Havekes LM, Lundholm E, Camejo G, Rensen PC, et al. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. Br J Pharmacol. 2009;156:1067-1675.
10. Qu S, Perdomo G, Su D, D'Souza FM, Shachter NS, Dong HH. Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice. J Lipid Res. 2007;48:1476-1487.
11. Wei J, Ouyang H, Wang Y, Pang D, Cong NX, Wang T, et al. Characterization of a hypertriglyceridemic transgenic miniature pig model expressing human apolipoprotein CIII. FEBS J. 2012;279:91-99.
12. Pan SY, Dong H, Han YF, Li WY, Zhao XY, Ko KM. A novel experimental model of acute hypertriglyceridemia induced by Schisandrin B. Eur J Pharmacol. 2006;537:200-204.
13. Pan SY, Dong H, Guo BF, Zhang Y, Yu ZL, Fong WF, et al. Effective kinetics of schisandrin B on serum/hepatic triglyceride and total cholesterol levels in mice with and without the influence of fenofibrate. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:585-591.
14. Depner CM, Torres-Gonzalez M, Tripathy S, Milne G, Jump DB. Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese ldlr-/- mice. J Nutr. 2012;142:1495-1503.
15. Ip SP, Poon MK, Wu SS, Che CT, Ng KH, Kong YC, et al. Effect of Schisandrin B on hepatic glutathione antioxidant system in mice: protection against carbon tetrachloride toxicity. Planta Med. 1995;61:398-401.
16. Pan SY, Dong H, Zhao XY, Xiang CJ, Fang HY, Fong WF, et al. Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice. J Pharm Pharmacol. 2008;60:399-403.
17. Zhang Q, Wang G, A J, Ma B, Dua Y, Zhu L, et al. Metabonomic profiling of diet-induced hyperlipidaemia in a rat model. Biomarkers. 2010;15:205-216.
18. Yang R, Guo P, Song X, Liu F, Gao N. Hyperlipidemic guinea pig model: mechanisms of triglyceride metabolism disorder and comparison to rat. Biol Pharm Bull. 2011;34:1046-1051.
19. Liu XM, Wu FH. [Comparison of animal models of hyperlipidemia]. J Chin Intergr Med. 2004;2:132-134. (text in Chinese with English abstract)
20. Jung SA, Choi M, Kim S, Yu R, Park T. Cinchonine prevents high-fat-diet-induced obesity through downregulation of adipogenesis and adipose inflammation. PPAR Res. 2012;2012:541204.
21. Liu D, He Z, Wu L, Fang Y. Effects of induction/inhibition of endogenous heme oxygenase-1 on lipid metabolism, endothelial function, and atherosclerosis in rabbits on a high fat diet. J Pharmacol Sci. 2012;118:14-24.
22. Lin ZJ, Zhang B, Liu XQ, Yang HL. Abdominal fat accumulation with hyperuricemia and hypercholesterolemia quail model induced by high fat diet. Chin Med Sci J. 2009;24:191-194.
23. Wang X, Hasegawa J, Kitamura Y, Wang Z, Matsuda A, Shinoda W, et al. Effects of hesperidin on the progression of hypercholesterolemia and fatty liver induced by high-cholesterol diet in rats. J Pharmacol Sci. 2011;117:129-138.
24. Gómez-Pérez Y, Capllonch-Amer G, Gianotti M, Lladó I, Proenza AM. Gómez-Pérez Y, et al. Long-term high-fat-diet feeding induces skeletal muscle mitochondrial biogenesis in rats in a sex-dependent and muscle-type specific manner. Nutr Metab (Lond). 2012;9:15.
25. Panossian A, Wikman GP. Pharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicine. J Ethnopharmacol. 2008;18:183-212.
26. Kim KJ, Yoon KY, Hong HD, Lee BY. Schisandra chinensis prevents hepatic lipid peroxidation and oxidative stress in rats subjected to heat environmental stress. Phytother Res. 2012;26:1674-1680.
27. Iqbal J, Hussain MM. Intestinal lipid absorption. Am J Physiol Endocrinol Metab. 2009;296:E1183-E1194.
28. Calkin AC, Tontonoz P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol. 2012;13:213-224.
29. Joseph B, Kapoor S, Schilsky ML, Gupta S. Bile salt-induced pro-oxidant liver damage promotes transplanted cell proliferation for correcting Wilson disease in the Long-Evans Cinnamon rat model. Hepatology. 2009;49:1616-1624.
30. Allen K, Kim ND, Moon JO, Copple BL. Upregulation of early growth response factor-1 by bile acids requires mitogen-activated protein kinase signaling. Toxicol Appl Pharmacol. 2010;243:63-67.
31. Gao X, Yuan S, Jayaraman S, Gursky O. Role of apolipoprotein A-II in the structure and remodeling of human high-density lipoprotein: protein conformational ensemble on various HDL. Biochemistry. 2012;51:4633-4641.
32. Kim JH, Jeong MH, Hong YJ, Lee KH, Kim IS, Choi YH, et al. Low density lipoprotein-cholesterol/high density lipoprotein-cholesterol ratio predicts plaque vulnerability in patients with stable angina. Korean Circ J. 2012;42:246-251.
33. Watanabe S, Tsuneyama K. Cattle bile but not bear bile or pig bile induces lipid profile changes and fatty liver injury in mice: mediation by cholic acid. J Toxicol Sci. 2012;37:105-121.
34. Leong PK, Chiu PY, Ko KM. Prooxidant-induced glutathione antioxidant response in vitro and in vivo: a comparative study between schisandrin B and curcumin. Biol Pharm Bull. 2012;35:464-472.
35. Lam PY, Leong PK, Chen N, Ko KM. Schisandrin B enhances the glutathione redox cycling and protects against oxidant injury in different types of cultured cells. Biofactors. 2011;37:439-446.
36. Giridharan VV, Thandavarayan RA, Bhilwade HN, Ko KM, Watanabe K, Konishi T. Schisandrin B, attenuates cisplatin-induced oxidative stress, genotoxicity and neurotoxicity through modulating NF-κB pathway in mice. Free Radic Res. 2012;46:50-60.
37. Tatewaki N, Nishida H, Yoshida M, Ando H, Kondo S, Sakamaki T, et al. Differential effect of Schisandrin B stereoisomers on ATR-mediated DNA damage checkpoint signaling. J Pharmacol Sci. 2013;122:138-148.
38. Krysiak R, Gdula-Dymek A, Okopien B. The effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances. Basic Clin Pharmacol Toxicol. 2013;112:198-202.
39. Maroy B. [Acute cholestatic hepatitis probably due to fenofibrate]. Therapie. 2010;65:147-148. (text in French)
40. Hajdu D, Aiglová K, Vinklerová I, Urbánek K. Acute cholestatic hepatitis induced by fenofibrate. J Clin Pharm Ther. 2009;34:599-602.
41. Ho CY, Kuo TH, Chen TS, Tsay SH, Chang FY, Lee SD. Fenofibrate-induced acute cholestatic hepatitis. J Chin Med Assoc. 2004;67:245-247.